ClinicalTrials.gg
RecruitingNCT06259123Updated Feb 15, 2024

Neoadjuvant PSMA-RLT in Oligometastatic PCa

A Phase 2 interventional study of [177Lu]Lu-PSMA I&T in Prostate Cancer, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Medical University of Vienna · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Prostatic Neoplasms with a site in Austria — 12 open to participants now, 30 under way, 19 of them phase 3. Prostatic Neoplasms · Austria.

Planned enrollment
83rd of 86
10 · median 679
Started
2024
with 3 others
Phase 2
13 of 99
2 open now
Primary completion
2027-01
later than 11 of 29 live
Registered
88th of 99
by date
Lead sponsor
8 of 99
Medical University of Vienna

Among the 99 studies in Prostatic Neoplasms with a site in Austria, this one is the 83rd largest by planned enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2024, is one of 13 in phase 2, reaches primary completion later than 11 of the 29 other live ones, and was the 88th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 99 studies in Prostatic Neoplasms with a site in Austria are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Prostatic Neoplasms with a site in Austria, or all of them as a file.
02

Study summary

Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy [177Lu]Lu-PSMAI\&T (PSMA-RLT) in patients planned for radical prostatectomy (RP) for oligometastatic prostate cancer (PCa) diagnosed using [68Ga]Ga-PSMA-11 PET examination.

Ten patients with oligometastatic primary PCa diagnosed using [68Ga]Ga-PSMA-11 PET-CT/MRI imaging will be included in this study.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • [177Lu]Lu-PSMAI&T
  • Oligometastatic prostate cancer
  • Radical prostatectomy
  • Therapy toxicity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Oligometastatic PCa diagnosed using [68Ga]Ga-PSMA-11 imaging defined as M1a and/or M1b positive with ≤5 osseous and/or M1c ≤3 lung metastases
  • (ECOG) Performance Status: 0-1
  • Patients must have adequate bone marrow reserve: WBC ≥1.5 x 109 /L, ≥100 x 109 /L and ≥9 g/dL.
  • Patients must have adequate renal function with ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL.
  • Patients must be able to sign Form

Exclusion criteria

Exclusion Criteria:

  • Concomitant participation in any other interventional trial
  • Concurrent severe oncologic and medical conditions that result in patients not having a of longer than the duration of the trial.
  • Nonmetastatic PCa on [68Ga]Ga-PSMA-11 imaging
  • >5 osseous on [68Ga]Ga-PSMA-11 imaging
  • Visceral metastases, apart from lungs
  • Age > 75 years.
  • Ongoing or previous androgen deprivation therapy with agonist or antagonist therapies.
  • Presence of somatic or psychiatric diseases that might interfere with the objectives and assessments of the study.
  • Complete urinary out-flow obstruction or severe unmanageable urinary incontinence
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA-11 PET imaging

    Patients with oligometastatic PCa diagnosed using \[68Ga\]Ga-PSMA-11 imaging defined as M1a and/or M1b positive with ≤5 osseous metastases and/or M1c ≤3 lung metastases will receive 2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy.

    Drug: [177Lu]Lu-PSMA I&T

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events [Safety and Tolerability] of neoadjuvant PSMA-RLT and radical prostatectomy

    Using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Furthermore, regular estimation of patient's ability to perform their usual everyday activities using Karnofsky performance status scale that ranges between a maximum of 100 percent (no restrictions) and 0 percent (death) and Eastern Cooperative Oncology Group Status scale that ranges from 0 (complete health) to 5 (death).

    Time frame: 12 months

Secondary outcomes

  1. PSA response to neoadjuvant PSMA-RLT and radical prostatectomy

    in term of PSA decline of ≥ 50% from baseline value

    Time frame: 24 months

  2. Imaging response and stability to neoadjuvant PSMA-RLT and radical prostatectomy

    in terms of disappearance of PSMA-avid lesions and/or size regression of the metastatic lymph nodes evaluated based on response evaluation criteria of solid tumor (RECIST) version 1.1.

    Time frame: 24 months

  3. Any therapy- and androgen deprivation therapy-free survival after radical prostatectomy,

    estimate the time until the start of any therapy- and androgen deprivation therapy

    Time frame: 24 months

  4. Estimate time to castration-resistant prostate cancer

    estimate the time until no PSA response in terms of PSA decline to androgen deprivation therapy

    Time frame: 24 months

  5. Evaluate pathologic response at radical prostatectomy

    measured as rates of pathologic complete response, minimal residual disease, pT3 disease, positive surgical margins, and lymph node metastasis.

    Time frame: 24 months

  6. Quantification of circulating free tumor DNA (ctDNA)

    enumeration of circulating tumor cells (CTCs) during the study period, molecular changes measured in liquid biopsy markers and tissue specimens following PSMA-RLT and radical prostatectomy and during follow-up.

    Time frame: 24 months

  7. Assess quality of life under the systemic PSMA-RLT

    using the questionnaires: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) and Functional Assessment of Chronic Illness Therapy (FACT-P).

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Upon request, we provide the individual participant data (IPD) available to other researchers.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: For 2 years after the end of the trail

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 35 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2023
First posted
Feb 14, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jun 2027
Last update
Feb 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06259123
Responsible party
Sazan Rasul, MD, PhD (Physician and post-doctoral researcher, Medical University of Vienna) — Principal investigator
First posted
Feb 14, 2024
Start date
Feb 1, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Feb 15, 2024

Study contacts

Sazan Rasul, PhD
Contact
sazan.rasul@meduniwien.ac.at
004314040058742
Shahrokh F. Shariat, Professor
Contact
shahrokh.shariat@meduniwien.ac.at
004314040026150

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium Lu 177 Zadavotide Guraxetan

Start the discussion